The Daily Biotech Pulse: Roche’s Alzheimer’s Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours:
Karyopharm Therapeutics’ Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies’ Asset Purchase Agreement dated January…
Looking Into Karyopharm Therapeutics’s Return On Capital Employed
Karyopharm Therapeutics (NASDAQ:KPTI) brought in sales totaling $47.67 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 206.92%, resulting in a loss of $41.40 million.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Karyopharm Therapeutics Earnings Preview
Karyopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Karyopharm Therapeutics will report an earnings per share (EPS) of $-0.63.
Aldeyra Therapeutics CFO Joshua Reed To Resign; Bruce Greenberg Appointed Interim CFO
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to
Karyopharm Appoints Reshma Rangwala As CMO
- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy -
- As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr.